New combo therapy aims to slow advanced rectal cancer in first-line trial
NCT ID NCT07383285
First seen Feb 03, 2026 · Last updated May 17, 2026 · Updated 10 times
Summary
This study tests whether adding radiation and two immunotherapy drugs to standard chemotherapy can help people with a specific type of advanced rectal cancer (RAS-mutant, MSS) live longer without the disease getting worse. About 106 adults aged 18-75 will be randomly assigned to receive either the standard treatment or the enhanced combination. The main goal is to see how many patients are still progression-free after 12 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL NEOPLASMS MALIGNANT are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.